IN2014DN09261A - - Google Patents
Info
- Publication number
- IN2014DN09261A IN2014DN09261A IN9261DEN2014A IN2014DN09261A IN 2014DN09261 A IN2014DN09261 A IN 2014DN09261A IN 9261DEN2014 A IN9261DEN2014 A IN 9261DEN2014A IN 2014DN09261 A IN2014DN09261 A IN 2014DN09261A
- Authority
- IN
- India
- Prior art keywords
- genomic locus
- target genomic
- compositions
- methods
- homologous recombination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638267P | 2012-04-25 | 2012-04-25 | |
| PCT/US2013/038165 WO2013163394A1 (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09261A true IN2014DN09261A (ru) | 2015-07-10 |
Family
ID=48289700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9261DEN2014 IN2014DN09261A (ru) | 2012-04-25 | 2013-04-25 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9834786B2 (ru) |
| EP (1) | EP2847335B1 (ru) |
| JP (1) | JP6275120B2 (ru) |
| KR (1) | KR101904508B1 (ru) |
| CN (2) | CN104364380B (ru) |
| AU (1) | AU2013251558B2 (ru) |
| BR (1) | BR112014026294B1 (ru) |
| CA (1) | CA2869016C (ru) |
| CY (1) | CY1120572T1 (ru) |
| DK (1) | DK2847335T3 (ru) |
| ES (1) | ES2683071T3 (ru) |
| HK (1) | HK1207396A1 (ru) |
| IL (1) | IL234905B (ru) |
| IN (1) | IN2014DN09261A (ru) |
| MX (1) | MX362523B (ru) |
| PL (1) | PL2847335T3 (ru) |
| PT (1) | PT2847335T (ru) |
| RU (1) | RU2645475C2 (ru) |
| SG (2) | SG11201406547YA (ru) |
| WO (1) | WO2013163394A1 (ru) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9834786B2 (en) | 2012-04-25 | 2017-12-05 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
| TR201806812T4 (tr) | 2012-05-25 | 2018-06-21 | Charpentier Emmanuelle | Rna-yönlendirmeli hedef dna modifikasyonu için ve rna-yönlendirmeli transkripsiyon modifikasyonu için yöntemler ve bileşimler. |
| KR102243092B1 (ko) | 2012-12-06 | 2021-04-22 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-기초된 유전체 변형과 조절 |
| SG11201505968WA (en) | 2013-02-20 | 2015-08-28 | Regeneron Pharma | Genetic modification of rats |
| SG11201508028QA (en) | 2013-04-16 | 2015-10-29 | Regeneron Pharma | Targeted modification of rat genome |
| CN105637087A (zh) * | 2013-09-18 | 2016-06-01 | 科马布有限公司 | 方法、细胞与生物体 |
| KR101566498B1 (ko) * | 2013-11-13 | 2015-11-06 | 건국대학교 산학협력단 | 인터루킨 2 수용체 감마 유전자 적중벡터, 그 벡터가 도입된 면역세포 결핍 형질전환 미니 복제돼지 생산과 그 제조방법 및 활용 |
| US10787684B2 (en) * | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| CA2933433C (en) * | 2013-12-11 | 2020-11-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| HUE049776T2 (hu) * | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| SG11201610633QA (en) * | 2014-06-26 | 2017-01-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| DK3207124T3 (da) | 2014-10-15 | 2019-08-12 | Regeneron Pharma | Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler |
| SI3221457T1 (sl) | 2014-11-21 | 2019-08-30 | Regeneron Pharmaceuticals, Inc. | Postopki in sestavki za ciljno genetsko modifikacijo z uporabo vodilnih RNK v parih |
| KR102530821B1 (ko) * | 2014-12-19 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물 |
| SG10201912899QA (en) | 2015-03-16 | 2020-02-27 | Regeneron Pharma | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
| AU2016270587B2 (en) | 2015-05-29 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a C9ORF72 locus |
| KR102294755B1 (ko) | 2016-09-30 | 2021-08-31 | 리제너론 파마슈티칼스 인코포레이티드 | C9orf72 유전자좌에서 헥사뉴클레오티드 반복 확장을 갖는 비인간 동물 |
| EP3644722A1 (en) | 2017-06-27 | 2020-05-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized asgr1 locus |
| EP3585160A2 (en) | 2017-07-31 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Crispr reporter non-human animals and uses thereof |
| SG11201911619YA (en) | 2017-07-31 | 2020-01-30 | Regeneron Pharma | Assessment of crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo |
| CN115074343A (zh) | 2017-07-31 | 2022-09-20 | 瑞泽恩制药公司 | Cas转基因小鼠胚胎干细胞和小鼠及其应用 |
| CA3071712C (en) | 2017-09-29 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus and methods of use |
| EP3585163B1 (en) | 2017-11-10 | 2022-03-09 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising slc30a8 mutation and methods of use |
| CN111655031B (zh) | 2017-11-30 | 2022-11-18 | 瑞泽恩制药公司 | 包含人源化trkb基因座的非人动物 |
| AU2019239880B2 (en) | 2018-03-19 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using CRISPR/Cas systems |
| CN112969367B (zh) | 2018-09-13 | 2023-04-07 | 瑞泽恩制药公司 | 作为c3肾小球病模型的补体因子h基因敲除大鼠 |
| CN116064550A (zh) | 2018-12-20 | 2023-05-05 | 瑞泽恩制药公司 | 核酸酶介导的重复扩增 |
| CN117178959A (zh) | 2019-04-04 | 2023-12-08 | 瑞泽恩制药公司 | 包括人源化凝血因子12基因座的非人动物 |
| AU2020286382A1 (en) | 2019-06-04 | 2021-11-04 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| CA3137764A1 (en) | 2019-06-07 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
| RU2722933C1 (ru) * | 2019-06-11 | 2020-06-05 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из бактерии demequina sediminicola |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| AU2021212668A1 (en) | 2020-01-28 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized PNPLA3 locus and methods of use |
| EP4099821A1 (en) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use |
| WO2021195079A1 (en) | 2020-03-23 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| US20230232796A1 (en) | 2020-06-26 | 2023-07-27 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
| WO2022187697A1 (en) | 2021-03-05 | 2022-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | In vivo dna assembly and analysis |
| AU2022381205A1 (en) | 2021-11-04 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified cacng1 locus |
| CA3238939A1 (en) | 2021-12-08 | 2023-06-15 | Gaurang Patel | Mutant myocilin disease model and uses thereof |
| WO2023122506A1 (en) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| WO2023154861A1 (en) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
| WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
| WO2024031053A1 (en) | 2022-08-05 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
| US20240224964A9 (en) | 2022-09-29 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| WO2024163650A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Animals comprising a modified klhdc7b locus |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| PT981637E (pt) | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
| US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| CA2354542A1 (en) | 1998-12-31 | 2000-07-06 | The J. David Gladstone Institutes | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
| JP2002535995A (ja) | 1999-02-03 | 2002-10-29 | ザ チルドレンズ メディカル センター コーポレイション | 染色体標的部位での二本鎖ｄｎａ切断の誘導を含む遺伝子修復 |
| EP1236045B1 (en) * | 1999-12-06 | 2005-11-09 | Sangamo Biosciences Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2003087341A2 (en) | 2002-01-23 | 2003-10-23 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| ATE531796T1 (de) * | 2002-03-21 | 2011-11-15 | Sangamo Biosciences Inc | Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination |
| EP1581610A4 (en) | 2002-09-05 | 2009-05-27 | California Inst Of Techn | USE OF CHIMERIC NUCLEASES TO STIMULATE GENE TARGETING |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| CA2513226A1 (en) * | 2003-01-13 | 2004-07-29 | Mahendra S. Rao | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
| ES2808687T3 (es) | 2003-08-08 | 2021-03-01 | Sangamo Therapeutics Inc | Métodos y composiciones para escisión dirigida y recombinación |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US20060063231A1 (en) | 2004-09-16 | 2006-03-23 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
| FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
| US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| US8110379B2 (en) | 2007-04-26 | 2012-02-07 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
| CN101784664B (zh) * | 2007-06-01 | 2013-04-10 | Omt公司 | 用于抑制内源性免疫球蛋白基因和生产转基因人独特型抗体的组合物和方法 |
| KR101759586B1 (ko) | 2008-08-22 | 2017-07-19 | 상가모 테라퓨틱스, 인코포레이티드 | 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물 |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| EP2180058A1 (en) | 2008-10-23 | 2010-04-28 | Cellectis | Meganuclease recombination system |
| CN102625655B (zh) | 2008-12-04 | 2016-07-06 | 桑格摩生物科学股份有限公司 | 使用锌指核酸酶在大鼠中进行基因组编辑 |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2421980A2 (en) | 2009-04-23 | 2012-02-29 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cancer |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| US8558055B2 (en) | 2009-07-24 | 2013-10-15 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| WO2011051390A1 (en) * | 2009-10-28 | 2011-05-05 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Homologous recombination in the oocyte |
| PT3147362T (pt) | 2009-10-29 | 2019-04-02 | Regeneron Pharma | Alelos multifuncionais |
| WO2011053957A2 (en) | 2009-11-02 | 2011-05-05 | Gen9, Inc. | Compositions and methods for the regulation of multiple genes of interest in a cell |
| CA2782596A1 (en) | 2009-12-01 | 2011-06-09 | National Cancer Center | Method for constructing chimeric rat using rat embryonic stem cells |
| HUE041436T2 (hu) | 2009-12-10 | 2019-05-28 | Univ Minnesota | Tal-effektor-közvetített DNS-módosítás |
| CA2783551A1 (en) | 2009-12-21 | 2011-06-30 | Keygene N.V. | Improved techniques for transfecting protoplasts |
| CN102843904B (zh) | 2010-01-22 | 2015-01-21 | 陶氏益农公司 | 在经遗传修饰的生物体中切除转基因 |
| CA2788850C (en) * | 2010-02-09 | 2019-06-25 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| GB201009732D0 (en) * | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| EP2579711B1 (en) | 2010-06-11 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Production of fertile xy female animals from xy es cells |
| US8945868B2 (en) * | 2010-07-21 | 2015-02-03 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a HLA locus |
| WO2012018726A1 (en) * | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| WO2012168307A2 (en) | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| LT2771357T (lt) | 2011-10-28 | 2018-10-25 | Regeneron Pharmaceuticals, Inc. | Pelės su genetiškai modifikuotu t ląstelių receptoriumi |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| US9834786B2 (en) | 2012-04-25 | 2017-12-05 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
| EP2847338B1 (en) | 2012-05-07 | 2018-09-19 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| TR201806812T4 (tr) | 2012-05-25 | 2018-06-21 | Charpentier Emmanuelle | Rna-yönlendirmeli hedef dna modifikasyonu için ve rna-yönlendirmeli transkripsiyon modifikasyonu için yöntemler ve bileşimler. |
| JP6279562B2 (ja) | 2012-06-12 | 2018-02-14 | ジェネンテック， インコーポレイテッド | 条件付きノックアウト対立遺伝子を生成するための方法および組成物 |
| CA2879997A1 (en) | 2012-07-25 | 2014-01-30 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
| EP4397759A2 (en) | 2012-10-23 | 2024-07-10 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| KR102243092B1 (ko) | 2012-12-06 | 2021-04-22 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-기초된 유전체 변형과 조절 |
| WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
| KR20150105956A (ko) | 2012-12-12 | 2015-09-18 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화 |
| AU2013359212B2 (en) | 2012-12-12 | 2017-01-19 | Massachusetts Institute Of Technology | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| US20140189896A1 (en) | 2012-12-12 | 2014-07-03 | Feng Zhang | Crispr-cas component systems, methods and compositions for sequence manipulation |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| EP2931892B1 (en) | 2012-12-12 | 2018-09-12 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| US20140242664A1 (en) | 2012-12-12 | 2014-08-28 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| EP2940140B1 (en) | 2012-12-12 | 2019-03-27 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| SG10201912991WA (en) | 2012-12-17 | 2020-03-30 | Harvard College | Rna-guided human genome engineering |
| JP6583918B2 (ja) | 2012-12-27 | 2019-10-02 | キージーン ナムローゼ フェンノートシャップ | 植物における遺伝連鎖を解消するための方法 |
| WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
| SG11201505968WA (en) | 2013-02-20 | 2015-08-28 | Regeneron Pharma | Genetic modification of rats |
| EP2958996B1 (en) | 2013-02-25 | 2019-10-16 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| WO2014131833A1 (en) | 2013-02-27 | 2014-09-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Gene editing in the oocyte by cas9 nucleases |
| US10612043B2 (en) | 2013-03-09 | 2020-04-07 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events |
| NZ712727A (en) | 2013-03-14 | 2017-05-26 | Caribou Biosciences Inc | Compositions and methods of nucleic acid-targeting nucleic acids |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| AU2014235968B2 (en) | 2013-03-21 | 2018-05-24 | Ospedale San Raffaele Srl | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CN105518146B (zh) | 2013-04-04 | 2022-07-15 | 哈佛学院校长同事会 | 利用CRISPR/Cas系统的基因组编辑的治疗性用途 |
| SG11201508028QA (en) | 2013-04-16 | 2015-10-29 | Regeneron Pharma | Targeted modification of rat genome |
| US20160040155A1 (en) | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| US20160186208A1 (en) | 2013-04-16 | 2016-06-30 | Whitehead Institute For Biomedical Research | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal |
| EP2796558A1 (en) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants |
| US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| CA2933433C (en) | 2013-12-11 | 2020-11-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| HUE049776T2 (hu) | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| SG11201610633QA (en) | 2014-06-26 | 2017-01-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| KR102530821B1 (ko) | 2014-12-19 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물 |
-
2013
- 2013-04-25 US US13/870,280 patent/US9834786B2/en active Active
- 2013-04-25 MX MX2014012994A patent/MX362523B/es active IP Right Grant
- 2013-04-25 IN IN9261DEN2014 patent/IN2014DN09261A/en unknown
- 2013-04-25 CA CA2869016A patent/CA2869016C/en active Active
- 2013-04-25 DK DK13720718.9T patent/DK2847335T3/en active
- 2013-04-25 ES ES13720718.9T patent/ES2683071T3/es active Active
- 2013-04-25 PL PL13720718T patent/PL2847335T3/pl unknown
- 2013-04-25 RU RU2014145942A patent/RU2645475C2/ru active
- 2013-04-25 KR KR1020147030262A patent/KR101904508B1/ko active IP Right Grant
- 2013-04-25 CN CN201380030738.6A patent/CN104364380B/zh active Active
- 2013-04-25 JP JP2015509128A patent/JP6275120B2/ja active Active
- 2013-04-25 WO PCT/US2013/038165 patent/WO2013163394A1/en active Application Filing
- 2013-04-25 PT PT137207189T patent/PT2847335T/pt unknown
- 2013-04-25 SG SG11201406547YA patent/SG11201406547YA/en unknown
- 2013-04-25 BR BR112014026294-2A patent/BR112014026294B1/pt active IP Right Grant
- 2013-04-25 CN CN201811024942.8A patent/CN109536526B/zh active Active
- 2013-04-25 EP EP13720718.9A patent/EP2847335B1/en active Active
- 2013-04-25 SG SG10201702445TA patent/SG10201702445TA/en unknown
- 2013-04-25 AU AU2013251558A patent/AU2013251558B2/en active Active
-
2014
- 2014-09-30 IL IL234905A patent/IL234905B/en active IP Right Grant
-
2015
- 2015-08-24 HK HK15108155.7A patent/HK1207396A1/xx unknown
-
2017
- 2017-10-24 US US15/792,112 patent/US10301646B2/en active Active
-
2018
- 2018-08-06 CY CY20181100810T patent/CY1120572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09261A (ru) | ||
| MY183741A (en) | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair | |
| AU2018201613B2 (en) | Optimal soybean loci | |
| EP4357452A3 (en) | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair | |
| EP3441468A3 (en) | Delivery methods and compositions for nuclease-mediated genome engineering | |
| MX2017008190A (es) | Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa. | |
| MX336846B (es) | Alteracion genomica dirigida. | |
| EP3313991A4 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| WO2013188522A3 (en) | Methods and compositions for generating conditional knock-out alleles | |
| WO2014153470A3 (en) | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases | |
| MX351043B (es) | Metodos para modificacion genomica. | |
| EP3057432A4 (en) | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells | |
| WO2015073683A3 (en) | Nuclease-mediated regulation of gene expression | |
| WO2014033644A3 (en) | Methods of nuclease-based genetic engineering | |
| MX364662B (es) | Óptimos loci de maíz. | |
| EP4234703A3 (en) | Genome engineering | |
| MX369747B (es) | Modificación dirigida del genoma de rata. | |
| EP3698631A3 (en) | Methods of delivering oligonucleotides to immune cells | |
| MX2016005874A (es) | Loci óptimos de soya. | |
| SG10201810110RA (en) | Extreme pcr | |
| WO2012166425A3 (en) | Methods of amplifying whole genome of a single cell | |
| NZ705742A (en) | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks | |
| IN2015DN01480A (ru) | ||
| SG10201809901SA (en) | Generating Pluripotent Cells De Novo | |
| MX2014003889A (es) | Compuestos antivirales. |